tbuckley/cabot-search huggingface dataset:
SP0182 Highlights from the pare programme at the 2018 eular congress
Authors: T Haugmark
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic inflammatory disease that is characterised by severe tissue damage and chronic synovial inflammation.<sup>1</sup> Using analysis of gene polymorphism, biochemical assays, and proteomics approaches, several promising biomarkers for treatment response have been proposed, including red blood cell (RBC) MTX polyglutamate levels, as well as serum levels of proteins such as cytokines, growth factors, and autoantibodies.<sup>2</sup> However, these markers need further development and refinement to attain sufficient sensitivity and specificity. <h3>Objectives</h3> In this study, we used a miRNAarray approach to identify new miRNA in exosome that are related to disease activity in patients with RA who showed inadequate response to treatment. We also examined the relationship between the levels of expression of the RNAs and various serologic parameters of the patients. <h3>Methods</h3> Forty-two RA patients were included in the study. Disease activity was measured using the 28-joint disease activity score with ESR (DAS28-ESR). Patients with RA were stratified according to the following criteria: the clinical remission (CR) group (n=22), DAS28-ESR≤2.6; and the non-CR group (n=20), DAS28-ESR&gt;2.6. By exosome preparation, miRNA array, and Reverse Transcription-qPCR reactions, several miRNAs were as potent markers for disease activity. <h3>Results</h3> After data processing for relative quantification of miRNA in exosome between the CR and non-CR groups, we identified 47 miRNAs with a relative fold change (non-CR/CR)&gt;2. The expression levels of 37 miRNAs were found decreased in non-CR group, while 10 miRNAs increased in non-CR group. To validate these results, five miRNAs were selected (hsa-miR-1915–3 p, hsa-miR-4516, has-miR-6511b-5p, hsa-miR-3665, hsa-miR-3613) showing at least 2-fold change between the CR and non-CR groups. Both levels of hsa-miR-1915–3 p and hsa-miR-6511b-5p were significantly increased in CR group; hsa-miR-1915–3 p was 43.75 in the CR group and 24.68 in the non-CR group (p=0.004), and hsa-miR-6511b-5p was 3.02 in the CR group and 2.45 in the non-CR group (p=0.03). <h3>Conclusions</h3> hsa-miR-1915–3 p showed promise as additional markers for evaluating disease activity in patients with RA. Prospective investigation of hsa-miR-1915–3 p may facilitate development of new diagnostic tools to assess disease activity and prognosis in RA and other autoimmune diseases. <h3>References</h3> [1] Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet(London, England) England 2001;358:903–11. [2] Halilova KI, Brown EE, Morgan SL, Bridges SL, Hwang MH, Arnett DK, et al. Markers of treatment response to methotrexate in rheumatoid arthritis: Where do we stand?Int J Rheumatol2012;2012. <h3>Acknowledgements</h3> NONE <h3>Disclosure of Interest</h3> None declared
Dry skin and skin barrier in early infancy
Authors: E.M. Rehbinder, A.J. Winger, L. Landrø, A. Asarnoj, T.L. Berents, K.H. Carlsen, G. Hedlin, C.M. Jonassen, B. Nordlund, L. Sandvik, H.O. Skjerven, C. Söderhäll, R. Vettukattil, K.C.L. Carlsen
Journal: British Journal of Dermatology (2019)
LFMM 2: Fast and Accurate Inference of Gene-Environment Associations in Genome-Wide Studies
Authors: Kevin Caye, Basile Jumentier, Johanna Lepeule, Olivier François
Journal: Molecular Biology and Evolution (2019)

Gene-environment association (GEA) studies are essential to understand the past and ongoing adaptations of organisms to their environment, but those studies are complicated by confounding due to unobserved demographic factors. Although the confounding problem has recently received considerable attention, the proposed approaches do not scale with the high-dimensionality of genomic data. Here, we present a new estimation method for latent factor mixed models (LFMMs) implemented in an upgraded version of the corresponding computer program. We developed a least-squares estimation approach for confounder estimation that provides a unique framework for several categories of genomic data, not restricted to genotypes. The speed of the new algorithm is several order faster than existing GEA approaches and then our previous version of the LFMM program. In addition, the new method outperforms other fast approaches based on principal component or surrogate variable analysis. We illustrate the program use with analyses of the 1000 Genomes Project data set, leading to new findings on adaptation of humans to their environment, and with analyses of DNA methylation profiles providing insights on how tobacco consumption could affect DNA methylation in patients with rheumatoid arthritis. Software availability: Software is available in the R package lfmm at https://bcm-uga.github.io/lfmm/.
SAT0711 Sense of coherence predicts development of chronic widespread pain over time
Authors: S. Hägerström, S. Bergman
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Chronic musculoskeletal pain is a common condition that has become a great challenge for those affected and for the society. Although much is known about factors that are associated with chronic pain, there is less of knowledge on the influence of salutogenetic factors as measured by sense of coherence (SOC) on pain, especially over time. <h3>Objectives</h3> To investigate the associations between SOC, health status and chronic musculoskeletal pain in a general population followed over 13 years. <h3>Methods</h3> A cross-sectional and longitudinal cohort study, based on a postal survey at baseline 2003 and a follow-up survey in 2016, including a sample of 1850 subjects from the general population. SOC was measured by a short three item questionnaire, SOC-3. Subjects were divided into three levels of SOC (low, moderate, high). Health status was measured by SF-36. Pain was reported on a pain mannequin with 18 predefined regions, and was categorised into three pain groups; no chronic pain (NCP), chronic regional pain (CRP), and chronic widespread pain (CWP). CWP was defined according to the <sup>ACR 1990</sup> criteria for fibromyalgia. The results were controlled for age and gender, and where appropriate also for pain group. <h3>Results</h3> Subjects with high SOC at baseline reported higher mean scores in all eight SF-36 dimensions than those with moderate or low SOC (p&lt;0.001 for all dimensions). Those with high SOC also reported a higher prevalence of NCP (66% vs. 34%) and a lower prevalence of CWP (8% vs. 33%) than subjects with low SOC (p&lt;0.001). In the long term follow-up a report of high SOC significantly (p&lt;0.001) predicted a better outcome with regard to development and persistence of CWP. Subjects with NCP and high SOC at baseline were less likely to report CWP in the thirteen-year follow-up than those with low SOC (3.6% vs. 10%). For those with CWP at baseline, subjects with high SOC more often reported less chronic pain (NCP or CRP) at follow-up compared to those with low SOC (43.5% vs. 20.5%). When controlled for age, gender and pain, there were no significant differences in SF-36 at follow-up for subjects with different level of SOC at baseline. <h3>Conclusions</h3> High level of SOC predicted a lower risk to develop CWP over time, and a better prognosis for those with CWP at baseline. The findings suggest that it would be beneficial to develop methods and make efforts to strengthen SOC, both when meeting patients in the clinic and when making interventions on a national level. <h3>Disclosure of Interest</h3> None declared
THU0659 Eurorheumavision: are the largest european rheumatology societies the ones with the most oral communications?
Authors: M. Paulino Huertas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Between June 14 ant 17,2017, coinciding with the 70th anniversary of its foundation, the annual EULAR congress took place in Madrid. With 14.000 participants from 130 countries,4845 accepted abstracts,2300 posters and more than 800 oral communications, it became a record congress in the history of European rheumatology. Now, EULAR is formed, among others, by 45 national rheumatology societies. Are the various countries proportionally represented at a scientific level? Those with the greatest number of rheumatologists have a greater weiight in communications to the congress? <h3>Objectives</h3> To assess the scientific weight of the different European rheumatological societies in the EULAR congress Secondary objective: To analyse the characteristics of these societies in terms of the number of rheumatologists, specialists for 100,0000 inhabitants and percentage with the total number of doctors <h3>Methods</h3> The scientific communications of the 2017 EULAR congress (Madrid) are analysed, according to the country of origin of the speakers. The number of rheumatologists in each country is assessed, their specific weight with respect to the total of European rheumatologists and in relation to the total number of doctors in their respective countries. <h3>Results</h3> Results: The countries with the highest number of rheumatologists in Western Europe are France 2,600, Italy (1800), Spain (1155), UK (950), Germany (800) and Netherlands (775). However, in number of communications The order changes, so the UK is the most productive (121), followed by the Netherlands (101), Germany (91), France (74), Italy (51), Sweden<sup>37</sup> and Spain.<sup>36</sup> In proportion, the Dutch presented 1 communication for every 7.6 rheumatologists, 1 German for every 8.7, 1 for every 7.8 British. The Mediterranean countries are far away, with 1 communication for every 32 Spanish rheumatologists and 1 for every 35 in the case of France and Italy <h3>Conclusions</h3> There is a marked disparity between the number of rheumatologists by country and number of oral communications. While the Netherlands, United Kingdom and Germany are protagonists of more than a third of the oral communications, nations such as Spain, France or Italy only contribute, together, to the 18% althought nearly 5600 rheumatologists work in their countries. Therefore, with twice as many specialists, they present half of communications. <h3>Disclosure of Interest</h3> None declared
Neural-Derived Extracellular Vesicles in Clinical Trials
Authors: Dena B. Dubal, Samuel J. Pleasure
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk
Authors: Vignesh A. Arasu, Diana L. Miglioretti, Brian L. Sprague, Nila H. Alsheik, Diana S.M. Buist, Louise M. Henderson, Sally D. Herschorn, Janie M. Lee, Tracy Onega, Garth H. Rauscher, Karen J. Wernli, Constance D. Lehman, Karla Kerlikowske
Journal: Journal of Clinical Oncology (2019)

To evaluate comparative associations of breast magnetic resonance imaging (MRI) background parenchymal enhancement (BPE) and mammographic breast density with subsequent breast cancer risk.
Abstract 14606: Cushing’S Sign and Higher Shock Index Are Predictors of the Life-threatening Pediatric Traumatic Brain Injury
Authors: Tetsuya Yumoto, Hiromichi Naito, Hiroki Maeyama, Yoshinori Kosaki, Kohei Tsukahara, Atsunori Nakao
Journal: Circulation (2017)

Introduction: Cushing’s reflex is a physiological response for increased intracranial pressure in patients with brain injury and is characterized by hypertension and bradycardia. Cushing’s sign has...
AB1045 Microproteinuria as a marker of subclinical gouty nephropathy
Authors: S. Smiyan, M. Franchuk, R. Komorovsky
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The prevalence of kidney damage in patients with gout ranges from 30% to 70%. Currently the concept of "gouty nephropathy" (GN) comprises all renal pathologies due to gout. There is no clear opinion whether hyperuricemia is a marker of renal dysfunction or risk factor. It is important to identify the early stages of GN as its course is subclinical for a long period of time. Microproteinuria is the first harbinger of kidney damage. However, predictors of GN have not been established for today. <h3>Objectives</h3> To establish predictors of GN. <h3>Methods</h3> A total of 103 patients with chronic gouty arthritis were examined in rheumathology depatment of Ternopil University Hospital. All patients had no history of any kidney disease. ELISA method was used to determine microproteins in urine. Subsequently, patients were divided into 2 groups: I (n=58) – patients with subclinical gouty nephropathy, abnormal microproteins level (56.3%), II (n=45) – control group, patients without kidney damage, normal microproteins level (43.7%). Statistical analysis was performed with STATISTICA software. <h3>Results</h3> Patients with subclinical gouty nephropathy had a higher prevalence of arterial hypertension and metabolic syndrome. The prevalence of osteoarthritis, diabetes mellitus and dyslipidemia was the same in both groups. Also, group I patients showed longer duration of the disease, greater radiologic changes, higher levels of hyperuricemia, tophi, work incapacity, greater number of affected joints and more frequent changes in urinalysis than the control group. <h3>Conclusions</h3> Formation of GN is asymptomatic, causing delays in early diagnosis, but can be suspended timely. Gouty nephropathy develops in 56.3% of patients with chronic gout arthritis, and manifestets by microproteinuria in the early subclinical stages. Duration of the disease, obesity, presence of tophi, arterial hypertension, hyperuricemia, increased triglycerols and low-density lipoproteins levels were found to be predictors of gouty nephropathy. <h3>References</h3> [1] Singh J. A., Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans IIAnn Rheum Dis2008;67:1310–1316. [2] Roddy E., Doherty M. Epidemiology of gout Arthritis Research &amp; Therapy2010;12(6):223–234. [3] Soriano L. C Contemporary epidemiology of gout in the UK general population. Arthritis Research &amp; Therapy2011;13(6):39–48. [4] Mazzalia M. Could uric acid have a pathogenic role in chronic allograft dysfunction. Arab Journal of Nephrology and Transplantation2009;2(3):37–41. <h3>Disclosure of Interest</h3> None declared
Survival And Pleurodesis Response Markers In Malignant Pleural Effusion-The Promise Study
Authors: I Psallidas, N Kanellakis, S Gerry, M Thezenas, C Phil, A Samsonova, H B Schiller, R Fischer, R Asciak, R Hallifax, R Mercer, M Dobson, T Dong, I Pavord, G Collins, B Kessler, H Pass, N Maskell, G Stathopoulos, N M Rahman
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Platelet-derived miR-223 promotes a phenotypic switch in arterial injury repair
Authors: Zhi Zeng, Luoxing Xia, Xuejiao Fan, Allison C. Ostriker, Timur Yarovinsky, Meiling Su, Yuan Zhang, Xiangwen Peng, Yi Xie, Lei Pi, Xiaoqiong Gu, Sookja Kim Chung, Kathleen A. Martin, Renjing Liu, John Hwa, Wai Ho Tang
Journal: Journal of Clinical Investigation (2019)

Upon arterial injury, endothelial denudation leads to platelet activation and delivery of multiple agents (e.g., TXA2, PDGF), promoting VSMC dedifferentiation and proliferation (intimal hyperplasia) during injury repair. The process of resolution of vessel injury repair, and prevention of excessive repair (switching VSMCs back to a differentiated quiescent state), is poorly understood. We now report that internalization of APs by VSMCs promotes resolution of arterial injury by switching on VSMC quiescence. Ex vivo and in vivo studies using lineage tracing reporter mice (PF4-cre × mT/mG) demonstrated uptake of GFP-labeled platelets (mG) by mTomato red-labeled VSMCs (mT) upon arterial wire injury. Genome-wide miRNA sequencing of VSMCs cocultured with APs identified significant increases in platelet-derived miR-223. miR-223 appears to directly target PDGFRβ (in VSMCs), reversing the injury-induced dedifferentiation. Upon arterial injury, platelet miR-223-KO mice exhibited increased intimal hyperplasia, whereas miR-223 mimics reduced intimal hyperplasia. Diabetic mice with reduced expression of miR-223 exhibited enhanced VSMC dedifferentiation and proliferation and increased intimal hyperplasia. Our results suggest that horizontal transfer of platelet-derived miRNAs into VSMCs provides a novel mechanism for regulating VSMC phenotypic switching. Platelets thus play a dual role in vascular injury repair, initiating an immediate repair process and, concurrently, a delayed process to prevent excessive repair.
CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics
Authors: Katherine Tarlock, Zixing Wang, Rory Rohm, Travis Biechele, Rhonda E. Ries, Tiffany Hylkema, Jatinder K Lamba, Gary D Means, Robert Thurman, Bill Arthur, Soheil Meshinchi
Journal: Blood (2018)
FRI0359 Routine clinical pathology measurements are associated with risk of organ damage accrual in sle
Authors: K. Zhang, S. Boyd, F. Petitjean, A. Hoi, R. Koelmeyer, E. Morand, H. Nim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity scores, which entail some subjectivity, are associated with damage accrual risk, but there have been few studies of objective measures as indicators of organ damage risk. Routine pathology laboratory measurements provide objective biological data, but their association with damage accrual in SLE has not been studied. <h3>Objectives</h3> To evaluate the association of objective pathology laboratory measurements with risk of organ damage accrual in SLE. <h3>Methods</h3> A dataset of SLE patients between 2007–2017 from the Australian Lupus Registry and Biobank was studied. Variables recorded prospectively included disease activity (SLEDAI-2k), drug treatment and 16 routine pathology measurements at each visit, and organ damage (SLICC-SDI) annually. Longitudinal patient data was split into annual periods, and each visit classified as being either in a "transition" or "non-transition" period based on whether SDI increased during that period. Time adjusted means (TAMs) of the variables were calculated for each period, and multivariable logistic regression analysis of the association with being in a "transition" period (adjusting for age, gender, race, previous organ damage and prednisolone dose) was performed, with Holm-Bonferroni correction. An "odds ratio plot" was generated to depict the effect on risk of organ damage accrual at each threshold of the continuous variables. <h3>Results</h3> 893 periods, comprising 5082 visits from 245 patients (85.6% female, 50.2% Caucasian), were analysed. Five out of 16 laboratory variables: estimated glomerular filtration rate (eGFR), creatinine (p&lt;0.01), urine protein:creatinine ratio (p&lt;0.01), ESR (p&lt;0.001), and haemoglobin (p&lt;0.001) were significantly associated with risk of damage increase. Moreover, the odds of damage increase were approximately proportional to the deviation of each of these variables from its respective normal range. SLEDAI-2k was also significantly associated with damage increase (p&lt;0.001), but the association of SLEDAI-2k with damage did not exhibit this proportionality. <h3>Conclusions</h3> Routine pathology measures were found to be proportionally associated with organ damage risk in SLE. The potential for the use of these measures as biomarkers, for example to generate an organ damage risk calculator for SLE, warrants further research. <h3>Disclosure of Interest</h3> None declared
AB0864 The impact of disease activity, structural damage, and fatigue on physical function in patients with ankylosing spondylitis: differences in early and late disease
Authors: J. He, I. Sari, R. Inman, N. Haroon
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with ankylosing spondylitis (AS), the physical function impairment caused by the disease is among the biggest concerns for both patients and clinicians. Previous studies have shown that disease activity and structural damage are the main underlying causes for physical function impairment. There is accumulating evidence that suggests fatigue as well contributes to functional limitations. However, the differential impact of these factors on physical function at early and late stage of disease remains unclear. <h3>Objectives</h3> Study the strength of association in AS patients with varying disease duration, between physical function and the three potential determinants of interest: disease activity, structural damage, and fatigue. <h3>Methods</h3> AS patients satisfying the modified New York criteria were followed from 2003 to 2017. Patients completed a standardised annual protocol including demographic and clinical factors, with radiographic data collected biennially. Baseline physical function (BASFI) was analysed for association with factors including disease activity (BASDAI), radiographic changes (mSASSS), and fatigue (FSS). The same analysis was conducted again with patients sub grouped with respect to disease duration (&lt;5 years, 5–9 years, 10–20 years,&gt;20 years), and again with respect to change in BASFI between the first and last patient visit. Multivariable regression analysis was performed to identify independent predictors of physical function at baseline and the change with time. <h3>Results</h3> A total of 611 patients were followed and completed the standard protocol (mean age at initial visit 38.2 years; 74% male; 76.5% HLA-B27+). At baseline BASFI was independently associated (table 1) with BASDAI (p&lt;0.0001), CRP (p&lt;0.0001), mSASSS (p&lt;0.0001), and FSS (p&lt;0.0001). In the disease duration subgroup analysis, BASFI was independently associated with BASDAI (p&lt;0.05) and mSASSS (p&lt;0.05) in all disease durations, and with FSS in subgroups with disease duration of 5 years or greater (p&lt;0.05). In the longitudinal analysis, change in BASFI was independently associated with changes in BASDAI (p&lt;0.0001) and FSS (p&lt;0.05), but not with change in mSASSS (p=0.283). <h3>Conclusions</h3> The study demonstrated that disease activity and structural changes consistently contributes to physical function impairment in both early and late stages of disease. Fatigue does not associate with physical function at early stages of the disease, but it increases in contribution to functional impairment as disease duration increases. <h3>Disclosure of Interest</h3> None declared